Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma
Open Access
Abstract
The promise of personalized medicine is a therapeutic advance where tumor signatures obtained from different omics platforms, such as genomics, transcriptomics, proteomics, and metabolomics, in addition to environmental factors including metals and metalloids, are used to guide the treatments. Clear cell renal carcinoma (ccRCC), the most common type of kidney cancer, can be sporadic (frequently) or genetic (rare), both characterized by loss of the von Hippel-Lindau (VHL) gene that controls hypoxia inducible factors. Recently, several genomic subtypes were identified with different prognoses. Transcriptomics, proteomics, metabolomics and metallomic data converge on altered metabolism as the principal feature of the disease. However, in view of multiple biochemical alterations and high level of tumor heterogeneity, identification of clearly defined subtypes is necessary for further improvement of treatments. In the future, single-cell combined multi-omics approaches will be the next generation of analyses gaining deeper insights into ccRCC progression and allowing for design of specific signatures, with better prognostic/predictive clinical applications.Keywords
Funding Information
- National Institutes of Health (R01GM128216)
- Veteran Administration, USA (2I01BX001110)
This publication has 115 references indexed in Scilit:
- Integrated molecular analysis of clear-cell renal cell carcinomaNature Genetics, 2013
- Reductive carboxylation supports growth in tumour cells with defective mitochondriaNature, 2011
- Urine Metabolomic Analysis Identifies Potential Biomarkers and Pathogenic Pathways in Kidney CancerOMICS: A Journal of Integrative Biology, 2011
- Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiencyProceedings of the National Academy of Sciences, 2011
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature, 2011
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1Molecular Cell, 2010
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal CarcinomaCancer Cell, 2008
- HIF and c-Myc: Sibling Rivals for Control of Cancer Cell Metabolism and ProliferationCancer Cell, 2007
- HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional ActivityCancer Cell, 2007
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005